Why the study?
Promoting the WHO action plan on aging requires innovative monitoring tools, as conventional biomarkers only provide episodic assessments once capacity has already declined.
Digital biomarkers may enable continuous, real-life monitoring and early diagnosis of intrinsic capacity decline in older adults compared to episodic conventional assessments.
Digital biomarkers may enable continuous remote monitoring in aging; leaves open validation before cardiovascular practice integration.
The WHO action plan on aging expects to change current clinical practices by promoting a more personalized model of medicine. To widely promote this initiative and achieve this goal, healthcare professionals need innovative monitoring tools. Use of conventional biomarkers (clinical, biological or imaging) provides a health status assessment at a given time once a capacity has declined. As a complement, continuous monitoring thanks to digital biomarkers makes it possible to remotely collect and analyze real life, ecologically valid, and continuous health related data. A seamless assessment of the patient's health status potentially enables early diagnosis of IC decline (e.g. sub-clinical or transient events not detectable by episodic evaluations) and investigation of its probable causes. This narrative review aims to develop the concept of digital biomarkers and its implementation in IC monitoring.
No takes yet. Share an insight, caveat, or question.
Piau et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: